Suresh K. Durgam's most recent trade in Intra-Cellular Therapies Inc was a trade of 13,133 Common Stock done . Disclosure was reported to the exchange on March 6, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Intra-Cellular Therapies Inc | Suresh K. Durgam | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2025 | 13,133 | 44,256 (0%) | 0% | - | Common Stock | |
Intra-Cellular Therapies Inc | Suresh K. Durgam | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2025 | 13,133 | 13,133 | - | - | Restricted Stock Units | |
Intra-Cellular Therapies Inc | Suresh K. Durgam | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2025 | 7,345 | 0 | - | - | Restricted Stock Units | |
Intra-Cellular Therapies Inc | Suresh K. Durgam | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2025 | 7,345 | 46,029 (0%) | 0% | - | Common Stock | |
Intra-Cellular Therapies Inc | Suresh K. Durgam | EVP, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 131.19 per share. | 06 Mar 2025 | 5,572 | 38,684 (0%) | 0% | 131.2 | 730,991 | Common Stock |
Intra-Cellular Therapies Inc | Suresh K. Durgam | EVP, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 131.24 per share. | 06 Mar 2025 | 3,116 | 42,913 (0%) | 0% | 131.2 | 408,944 | Common Stock |
Intra-Cellular Therapies Inc | Suresh K. Durgam | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 8,742 | 17,485 | - | - | Restricted Stock Units | |
Intra-Cellular Therapies Inc | Suresh K. Durgam | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 8,742 | 34,832 (0%) | 0% | - | Common Stock | |
Intra-Cellular Therapies Inc | Suresh K. Durgam | EVP, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 128.20 per share. | 01 Mar 2025 | 3,709 | 31,123 (0%) | 0% | 128.2 | 475,494 | Common Stock |
Intra-Cellular Therapies Inc | Suresh K. Durgam | EVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 24,621 | 24,621 | - | - | Restricted Stock Units | |
Intra-Cellular Therapies Inc | Suresh K. Durgam | EVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 11,017 | 30,820 (0%) | 0% | 0 | Common Stock | |
Intra-Cellular Therapies Inc | Suresh K. Durgam | EVP, Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 127.00 per share. | 31 Jan 2025 | 4,730 | 26,090 (0%) | 0% | 127 | 600,710 | Common Stock |
Intra-Cellular Therapies Inc | Suresh K. Durgam | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2024 | 7,345 | 23,515 (0%) | 0% | - | Common Stock | |
Intra-Cellular Therapies Inc | Suresh K. Durgam | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2024 | 7,345 | 7,345 | - | - | Restricted Stock Units | |
Intra-Cellular Therapies Inc | Suresh K. Durgam | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 66.34 per share. | 07 Mar 2024 | 3,728 | 18,892 (0%) | 0% | 66.3 | 247,316 | Common Stock |
Intra-Cellular Therapies Inc | Suresh K. Durgam | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 66.86 per share. | 07 Mar 2024 | 2,722 | 16,170 (0%) | 0% | 66.9 | 181,993 | Common Stock |
Intra-Cellular Therapies Inc | Suresh K. Durgam | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 65.06 per share. | 07 Mar 2024 | 2,179 | 21,336 (0%) | 0% | 65.1 | 141,766 | Common Stock |
Intra-Cellular Therapies Inc | Suresh K. Durgam | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 65.89 per share. | 07 Mar 2024 | 872 | 20,464 (0%) | 0% | 65.9 | 57,456 | Common Stock |
Intra-Cellular Therapies Inc | Suresh K. Durgam | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 66.96 per share. | 07 Mar 2024 | 661 | 19,803 (0%) | 0% | 67.0 | 44,261 | Common Stock |
Intra-Cellular Therapies Inc | Suresh K. Durgam | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2024 | 13,132 | 26,266 | - | - | Restricted Stock Units | |
Intra-Cellular Therapies Inc | Suresh K. Durgam | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2024 | 13,132 | 22,620 (0%) | 0% | - | Common Stock | |
Intra-Cellular Therapies Inc | Suresh K. Durgam | EVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 26,227 | 26,227 | - | - | Restricted Stock Units | |
Intra-Cellular Therapies Inc | K. Durgam Suresh | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 7,907 | 13,600 (0%) | 0% | - | Common Stock | |
Intra-Cellular Therapies Inc | Durgam K. Suresh | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 7,907 | 0 | - | - | Restricted Stock Units | |
Intra-Cellular Therapies Inc | Suresh K. Durgam | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 70.16 per share. | 23 Feb 2024 | 1,400 | 10,800 (0%) | 0% | 70.2 | 98,224 | Common Stock |
Intra-Cellular Therapies Inc | K. Suresh Durgam | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 69.38 per share. | 23 Feb 2024 | 1,400 | 12,200 (0%) | 0% | 69.4 | 97,132 | Common Stock |
Intra-Cellular Therapies Inc | K. Durgam Suresh | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 71.02 per share. | 23 Feb 2024 | 1,312 | 9,488 (0%) | 0% | 71.0 | 93,178 | Common Stock |
Intra-Cellular Therapies Inc | Suresh Durgam K. | EVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 11,860 | 11,860 (0%) | 0% | 0 | Common Stock | |
Intra-Cellular Therapies Inc | Suresh K. Durgam | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 67.49 per share. | 01 Feb 2024 | 3,847 | 5,693 (0%) | 0% | 67.5 | 259,634 | Common Stock |
Intra-Cellular Therapies Inc | Suresh Durgam K. | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 66.69 per share. | 01 Feb 2024 | 2,320 | 9,540 (0%) | 0% | 66.7 | 154,721 | Common Stock |
Intra-Cellular Therapies Inc | Durgam Suresh K. | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2024 | 62,282 | 0 | - | - | Stock Option (right to buy) | |
Intra-Cellular Therapies Inc | Durgam Suresh K. | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.87 per share. | 02 Jan 2024 | 62,282 | 62,282 (0%) | 0% | 19.9 | 1,237,543 | Common Stock |
Intra-Cellular Therapies Inc | K. Suresh Durgam | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 70.41 per share. | 02 Jan 2024 | 37,427 | 24,855 (0%) | 0% | 70.4 | 2,635,235 | Common Stock |
Intra-Cellular Therapies Inc | Suresh K. Durgam | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 70.80 per share. | 02 Jan 2024 | 22,645 | 2,210 (0%) | 0% | 70.8 | 1,603,266 | Common Stock |
Intra-Cellular Therapies Inc | K. Durgam Suresh | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 71.77 per share. | 02 Jan 2024 | 2,210 | 0 (0%) | 0% | 71.8 | 158,612 | Common Stock |
Intra-Cellular Therapies Inc | Durgam Suresh K. | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 65.00 per share. | 13 Dec 2023 | 21,262 | 0 (0%) | 0% | 65 | 1,382,030 | Common Stock |
Intra-Cellular Therapies Inc | Suresh K. Durgam | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 65.00 per share. | 17 Jul 2023 | 1,842 | 21,262 (0%) | 0% | 65 | 119,730 | Common Stock |
Intra-Cellular Therapies Inc | Suresh K. Durgam | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 7,344 | 30,448 (0%) | 0% | - | Common Stock | |
Intra-Cellular Therapies Inc | Suresh K. Durgam | EVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 7,344 | 14,690 | - | - | Restricted Stock Units | |
Intra-Cellular Therapies Inc | Suresh K. Durgam | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 45.08 per share. | 10 Mar 2023 | 6,998 | 23,450 (0%) | 0% | 45.1 | 315,470 | Common Stock |
Intra-Cellular Therapies Inc | Suresh K. Durgam | EVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 44.29 per share. | 10 Mar 2023 | 346 | 23,104 (0%) | 0% | 44.3 | 15,324 | Common Stock |
Intra-Cellular Therapies Inc | Suresh K. Durgam | EVP, Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 39,398 | 39,398 | - | - | Restricted Stock Units | |
Intra-Cellular Therapies Inc | Suresh K. Durgam | SVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2023 | 7,906 | 7,907 | - | - | Restricted Stock Units | |
Intra-Cellular Therapies Inc | Suresh K. Durgam | SVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2023 | 7,906 | 31,010 (0%) | 0% | - | Common Stock | |
Intra-Cellular Therapies Inc | Suresh K. Durgam | SVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 47.14 per share. | 23 Feb 2023 | 7,906 | 23,104 (0%) | 0% | 47.1 | 372,689 | Common Stock |
Intra-Cellular Therapies Inc | Suresh K. Durgam | SVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2023 | 8,354 | 0 | - | - | Restricted Stock Units | |
Intra-Cellular Therapies Inc | Suresh K. Durgam | SVP, Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2023 | 8,354 | 31,458 (0%) | 0% | - | Common Stock | |
Intra-Cellular Therapies Inc | Suresh K. Durgam | SVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 46.55 per share. | 18 Feb 2023 | 6,673 | 24,785 (0%) | 0% | 46.5 | 310,628 | Common Stock |
Intra-Cellular Therapies Inc | Suresh K. Durgam | SVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 48.63 per share. | 18 Feb 2023 | 806 | 23,179 (0%) | 0% | 48.6 | 39,196 | Common Stock |
Intra-Cellular Therapies Inc | Suresh K. Durgam | SVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 47.20 per share. | 18 Feb 2023 | 800 | 23,985 (0%) | 0% | 47.2 | 37,760 | Common Stock |
Intra-Cellular Therapies Inc | Suresh K. Durgam | SVP, Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 49.60 per share. | 18 Feb 2023 | 75 | 23,104 (0%) | 0% | 49.6 | 3,720 | Common Stock |
Intra-Cellular Therapies Inc | Suresh K. Durgam | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 22,034 | 22,034 | - | - | Restricted Stock Units | |
Intra-Cellular Therapies Inc | Suresh K. Durgam | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 17,916 | 17,916 | - | - | Stock Option (right to buy) | |
Intra-Cellular Therapies Inc | Suresh K. Durgam | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 56.98 per share. | 02 Mar 2022 | 4,177 | 26,964 (0%) | 0% | 57.0 | 238,005 | Common Stock |
Intra-Cellular Therapies Inc | Suresh K. Durgam | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 55.52 per share. | 02 Mar 2022 | 3,860 | 23,104 (0%) | 0% | 55.5 | 214,307 | Common Stock |
Intra-Cellular Therapies Inc | Suresh K. Durgam | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 8,354 | 31,458 (0%) | 0% | - | Common Stock | |
Intra-Cellular Therapies Inc | Suresh K. Durgam | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 8,354 | 8,354 | - | - | Restricted Stock Units | |
Intra-Cellular Therapies Inc | Suresh K. Durgam | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 55.53 per share. | 18 Feb 2022 | 2,820 | 28,638 (0%) | 0% | 55.5 | 156,595 | Common Stock |
Intra-Cellular Therapies Inc | Suresh K. Durgam | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 54.80 per share. | 18 Feb 2022 | 1,357 | 27,281 (0%) | 0% | 54.8 | 74,364 | Common Stock |
Intra-Cellular Therapies Inc | Suresh K. Durgam | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 42.03 per share. | 18 Jan 2022 | 6,223 | 23,104 (0%) | 0% | 42.0 | 261,553 | Common Stock |
Intra-Cellular Therapies Inc | Suresh K. Durgam | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jan 2022 | 13,093 | 36,197 (0%) | 0% | - | Common Stock | |
Intra-Cellular Therapies Inc | Suresh K. Durgam | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jan 2022 | 13,093 | 0 | - | - | Restricted Stock Units | |
Intra-Cellular Therapies Inc | Suresh K. Durgam | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 40.63 per share. | 08 Jan 2022 | 4,850 | 29,827 (0%) | 0% | 40.6 | 197,056 | Common Stock |
Intra-Cellular Therapies Inc | Suresh K. Durgam | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 41.48 per share. | 08 Jan 2022 | 1,520 | 34,677 (0%) | 0% | 41.5 | 63,050 | Common Stock |
Intra-Cellular Therapies Inc | Suresh K. Durgam | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 39.83 per share. | 08 Jan 2022 | 500 | 29,327 (0%) | 0% | 39.8 | 19,915 | Common Stock |
Intra-Cellular Therapies Inc | Suresh K. Durgam | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2021 | 23,719 | 23,719 | - | - | Restricted Stock Units | |
Intra-Cellular Therapies Inc | Suresh K. Durgam | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2021 | 18,714 | 18,714 | - | - | Stock Option (right to buy) | |
Intra-Cellular Therapies Inc | Suresh K. Durgam | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2021 | 8,354 | 25,838 (0%) | 0% | - | Common Stock | |
Intra-Cellular Therapies Inc | Suresh K. Durgam | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2021 | 8,354 | 16,708 | - | - | Restricted Stock Units | |
Intra-Cellular Therapies Inc | Suresh K. Durgam | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 39.28 per share. | 18 Feb 2021 | 2,534 | 23,304 (0%) | 0% | 39.3 | 99,536 | Common Stock |
Intra-Cellular Therapies Inc | Suresh K. Durgam | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 38.87 per share. | 18 Feb 2021 | 200 | 23,104 (0%) | 0% | 38.9 | 7,774 | Common Stock |
Intra-Cellular Therapies Inc | Suresh K. Durgam | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jan 2021 | 13,092 | 13,093 | - | - | Restricted Stock Units | |
Intra-Cellular Therapies Inc | Suresh K. Durgam | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jan 2021 | 13,092 | 21,851 (0%) | 0% | - | Common Stock | |
Intra-Cellular Therapies Inc | Suresh K. Durgam | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 32.13 per share. | 08 Jan 2021 | 4,267 | 17,584 (0%) | 0% | 32.1 | 137,099 | Common Stock |
Intra-Cellular Therapies Inc | Suresh K. Durgam | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 31.60 per share. | 08 Jan 2021 | 100 | 17,484 (0%) | 0% | 31.6 | 3,160 | Common Stock |